Intralesional RNA Immunotherapy Shows Promise for BCC

https://www.medscape.com/viewarticle/intralesional-rna-immunotherapy-shows-promise-bcc-2026a10010qi?src= VIENNA — More than half of patients with high-risk basal cell carcinoma (BCC) of the head and neck (18 of 32; 56%) had no visible tumor and no viable tumor on pathology 24 weeks after three intralesional injections of the experimental RNA immunotherapy BO-112, a phase 2b trial found. The complete response rate was slightly higher among the subgroup of patients with high-risk facial lesions, at 62% (16 of 26). https://www.medscape.com/c25/p14/european-academy-dermatology-and-venereology-eadv-2026-2026a1000xdj European Academy of Dermatology and Venereology (EADV) 2026 Congress